Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Postoperative Pain, Acute, Skin Cancer
Interventions
Meloxicam 7.5 mg, Meloxicam 15 mg, Acetaminophen 500mg
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 110 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Shoulder Pain, Opioid Use
Interventions
Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

NCT00618163
Conditions
Inflammation
Interventions
Meloxicam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions
ZYNRELEF 200Mg-6Mg Extended-Release Solution
Drug
Lead sponsor
Dr. Yannis Raftopoulos
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Holyoke, Massachusetts
Completed Phase 3 Interventional Results available

Study of Post-Herniorrhaphy Non-opioid MMA Regimens

NCT03907176
Conditions
Analgesia
Interventions
HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Anaheim, California • La Mesa, California • Orange, California + 22 more
Conditions
Rotator Cuff Repairs, Pain Management
Interventions
Multimodal Pain Regimen, Standard of Care Pain Regimen
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Bunion of Unspecified Foot, Bunionette of Unspecified Foot, Hammertoe, Ankle Fractures, Achilles Tendon Surgery
Interventions
Acetominophen, Toradol, Meloxicam, Cyclobenzaprine, Lyrica
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Completed Phase 2 Interventional Results available

Phase 2B Upper Extremity Nerve Block Study

NCT03011333
Conditions
Postoperative Pain
Interventions
HTX-011, Bupivacaine HCl without epinephrine, Saline Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Pasadena, California • Houston, Texas
Not listed Phase 3 Interventional Accepts healthy volunteers

Pain Relief After PrimaryTKA

NCT05751421
Conditions
Pain, Postoperative
Interventions
Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement
Drug · Procedure
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Orthopaedic Fractures
Interventions
NSAID, Gabapentinoids, placebo
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
17
States / cities
Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grosse Pointe Farms, Michigan
Conditions
Osteoarthritis
Interventions
Meloxicam Test Capsules
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 32 more
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
meloxicam oral suspension, naproxen oral suspension
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
29
States / cities
Little Rock, Arkansas • Madera, California • San Diego, California + 25 more
Completed Phase 3 Interventional Results available

Evaluation of Preoperative N1539 in Colorectal Surgery

NCT03323385
Conditions
Pain, Postoperative
Interventions
N1539, Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Florence, Alabama • Mobile, Alabama • Miami, Florida + 6 more
Completed Phase 3 Interventional Results available

Maximizing Outcomes in Treating Acute Migraine

NCT03896009
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 80 more
Completed Phase 2 Interventional Results available

Pilot Herniorrhaphy Study for Postoperative Analgesia

NCT02504580
Conditions
Postoperative Pain
Interventions
HTX-011, Placebo, HTX-002, Bupivacaine HCI (Marcaine), HTX-011A, HTX-011B, HTX-009
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Anaheim, California • Houston, Texas
Conditions
Postoperative Pain, Bunions
Interventions
HTX-011A, Saline Placebo, HTX-011B, HTX-002, Bupivacaine HCl, HTX-009
Drug · Biological
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • Bakersfield, California • Pasadena, Maryland + 2 more
Completed Phase 2 Interventional Results available

Meloxicam vs Placebo for Mobilization

NCT02003625
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
Interventions
GCSF, meloxicam, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Opioid Use, Pain, Post Operative
Interventions
nCAP Signal Relief Patch, Standard of Care
Device · Other
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Postoperative Pain
Interventions
HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Zynrelef Versus Adductor Canal Block

NCT07216586
Conditions
Knee Osteoarthritis, Arthritis Knee
Interventions
ZYNRELEF 400Mg-12Mg Extended-Release Solution, Ultrasound-Guided Adductor Canal Block, Ropivacaine 0.5% Injectable Solution
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 1Phase 2 Interventional Results available

Dose-Escalation Study of HTX-034 Following Bunionectomy

NCT04398329
Conditions
Bunions, Postoperative Pain
Interventions
HTX-034 low dose, HTX-034 high dose, Luer lock applicator, Bupivacaine HCl
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Bellaire, Texas • San Antonio, Texas + 1 more
Conditions
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Meloxicam Tablets Under Fed Conditions

NCT00601887
Conditions
Inflammation
Interventions
Meloxicam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas